Classification of Chronic Myeloproliferative Diseases by Bone Marrow Biopsies

2015 ◽  
pp. 41-56
Author(s):  
Alexander Georgii ◽  
Karl F. Vykoupil ◽  
Juergen Thiele
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Biopsies ◽  
Myeloproliferative Diseases ◽  
Chronic Myeloproliferative Diseases

Hanover Classification of Chronic Myeloproliferative Diseases by Histopathology of the Bone Marrow

Leukemias ◽  
1993 ◽  
pp. 259-265
Author(s):  
A. George ◽  
K. F. Vykoupil ◽  
T. Buhr ◽  
M. Dominis ◽  
U. Döhler ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Myeloproliferative Diseases ◽  
Chronic Myeloproliferative Diseases

Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation

Blood ◽  
2007 ◽  
Vol 110 (1) ◽  
pp. 354-359 ◽  
Author(s):  
Luciana Teofili ◽  
Maurizio Martini ◽  
Tonia Cenci ◽  
Giovanna Petrucci ◽  
Lorenza Torti ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Expression Pattern ◽  
Staining Pattern ◽  
Moderate Increase ◽  
Jak2 Mutation ◽  
Bone Marrow Biopsies ◽  
Molecular Defects ◽  
Bone Marrow Histology ◽  
Myeloproliferative Diseases ◽  
Chronic Myeloproliferative Diseases

The V617F JAK2 mutation reported in Ph-negative myeloproliferative diseases (MPDs) induces the constitutive activation of JAK2, which produces an increased phosphorylation of signal transducer activator of transcription (STAT). In this study, we have analyzed a series of 114 patients (54 with polycythemia vera [PV], 44 with essential thrombocythemia [ET], 12 with idiopathic myelofibrosis [IM], and 4 with myelofibrosis secondary to MPD) for the expression pattern of phosphorylated STAT-3 and STAT-5 (pSTAT-3 and pSTAT-5, respectively) by immunostaining bone marrow biopsies. We found 3 specific patterns of pSTAT-3 and pSTAT-5 expression, significantly different from the normal staining pattern: uniformly increased pSTAT-3 and pSTAT-5 expression in PV, increased pSTAT-3 and reduced pSTAT-5 expression in ET, and uniformly reduced pSTAT-3 and pSTAT-5 expression in IM. A moderate increase of pSTAT-3 and pSTAT-5 expression was observed in secondary forms of erythrocytosis and thrombocytosis. In all evaluated MPDs, the pSTAT-5 and pSTAT-3 expression pattern was not influenced by the presence of V617F JAK2 mutation. These findings underline the importance of bone marrow histology in the differential diagnosis of Ph-negative MPD and support the hypothesis that V617F mutation simply contributes with other molecular defects in allowing the PV, ET, or IM phenotype to emerge.

Expression of adhesion factor CD239 in bone marrow cells in chronic myeloproliferative diseases

2008 ◽  
Vol 28 (3) ◽  
pp. 299-303
Author(s):  
Kais Hussein ◽  
Katharina Theophile ◽  
Katrin Denzer ◽  
Hans Kreipe ◽  
Oliver Bock
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Myeloproliferative Diseases ◽  
Adhesion Factor ◽  
Chronic Myeloproliferative Diseases ◽  
Marrow Cells

CD34/QBEND10 immunostaining in bone marrow biopsies: an additional parameterfor the diagnosis and classification of myelodysplastic syndromes

2000 ◽  
Vol 64 (2) ◽  
pp. 71-79 ◽  
Author(s):  
Audrey S. Baur ◽  
Christiane Meugé-Moraw ◽  
Pierre-Michel Schmidt ◽  
Valérie Parlier ◽  
Martine Jotterand ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Myelodysplastic Syndromes ◽  
Bone Marrow Biopsies ◽  
Diagnosis And Classification

Cutaneous ulcers following hydroxyurea therapy

Phlebologie ◽  
2004 ◽  
Vol 33 (06) ◽  
pp. 202-205 ◽  
Author(s):  
K. Hartmann ◽  
S. Nagel ◽  
T. Erichsen ◽  
E. Rabe ◽  
K. H. Grips ◽  
...  
Keyword(s):  
Side Effects ◽  
Side Effect ◽  
Antineoplastic Agent ◽  
Limited Time ◽  
Myeloproliferative Diseases ◽  
Dermatological Side Effects ◽  
Chronic Myeloproliferative Diseases ◽  
Hydroxyurea Therapy

SummaryHydroxyurea (HU) is usually a well tolerated antineoplastic agent and is commonly used in the treatment of chronic myeloproliferative diseases. Dermatological side effects are frequently seen in patients receiving longterm HU therapy. Cutaneous ulcers have been reported occasionally.We report on four patients with cutaneous ulcers whilst on long-term hydroxyurea therapy for myeloproliferative diseases. In all patients we were able to reduce the dose, or stop HU altogether and their ulcers markedly improved. Our observations suggest that cutaneous ulcers should be considered as possible side effect of long-term HU therapy and healing of the ulcers can be achieved not only by cessation of the HU treatment, but also by reducing the dose of hydroxyurea for a limited time.

Epiphyseal bone-marrow abnormalities and restitution in legg-calvé-perthes disease

1997 ◽  
Vol 38 (5) ◽  
pp. 855-862 ◽  
Author(s):  
P. Hochbergs ◽  
G. Eckervall ◽  
H. Wingstrand ◽  
N. Egund ◽  
K. Jonsson
Keyword(s):  
Bone Marrow ◽  
Mr Imaging ◽  
Perthes Disease ◽  
Mr Images ◽  
Group I ◽  
Radiological Classification ◽  
Signal Changes ◽  
Over Time ◽  
Epiphyseal Bone

Purpose: By means of MR imaging, to determine signal abnormalities in the femoral epiphysis; to determine their location, extent and restitution over time; and to correlate these findings to the Catterall radiological classification. Material and Methods: A total of 247 MR images in 86 patients (101 hips) with Legg-CalvC-Perthes disease were examined. The MR images were taken in the coronal plane, and the images through the center of the femoral head were used for this study. Results: T1-weighted images proved as good as T2-weighted images for the MR evaluation of the extent of the necrosis. In almost every case, the central-cranial part of the epiphysis showed a low initial signal. In Catterall group I, the medial part was never involved. In Catterall III and IV, almost the entire epiphysis showed signal changes. In the period 3–6 years after diagnosis, we still found signal changes in the epiphysis in some hips but there was no correlation with the Catterall classification. After 6 years, the epiphysis showed normal signal intensity in MR imaging. In T1-weighted images, Gd-enhancement occurred in the peripheral regions in the early stages of the disease. The central part of the epiphysis became more enhanced over time and peaked in the period 1–3 years after diagnosis. Conclusion: MR is a valuable modality for monitoring changes in the femoral epiphysis. We propose a new classification of the extent and pattern of epiphyseal bone-marrow abnormalities based on the 4 zones most commonly observed in MR imaging.

Sign in / Sign up

Export Citation Format

Share Document